Myasthenia gravis and diabetes mellitus: - A 35-year retrospective study

11Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Background: The most common treatment of myasthenia gravis is high-dose prednisolone administration and thymectomy. A well-known adverse effect of prednisolone is hyperglycemia, however, to date there is no such detailed report. Patients and Methods: We treated 325 myasthenia gravis patients in a recent 35 years period, and found 11 patients with diabetes mellitus. We compared these 11 diabetic patients with previously-reported cases. Results: These 11 patients did not have any antibody against β-cells in the pancreas such as anti-glutamic acid decarboxylase antibody. In 10 of 11 patients diabetes mellitus was controlled with oral medications. Conclusion: Myasthenic patients with diabetes mellitus could be classified into 2 groups, one group with positive organ-specific autoantibodies to many organs (with type 1 diabetes mellitus), and the other group with diabetes mellitus onset during prednisolone administration (with type 2 diabetes mellitus). © 2007 The Japanese Society of Internal Medicine.

Cite

CITATION STYLE

APA

Wakata, N., Nemoto, H., Konno, S., Nakazora, H., Nomoto, N., Sugimoto, H., & Kurihara, T. (2007). Myasthenia gravis and diabetes mellitus: - A 35-year retrospective study. Internal Medicine, 46(9), 557–559. https://doi.org/10.2169/internalmedicine.46.6237

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free